- Home
- Companies
- switzerland
- infusion solution
Refine by
Infusion Solution Suppliers In Switzerland
4 companies found
based inRotkreuz, SWITZERLAND
About SalvisLab Renggli AG, founded in 1927, is an established Swiss family enterprise with international orientation in the realm of complete laboratory solutions. As one of the leading European manufacturers and market leaders in Switzerland, ...
The HC120 heating cabinet was specially developed and manufactured for the care and surgical sector, traumatology, intensive care units, baby units, maternity wards, old-age and care homes, therapy units, physiotherapy, wellness areas, etc. The ...
based inLausanne, SWITZERLAND
Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug ...
Oxaliplatin is a diaminocyclohexane (DACH) platin. It is the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®, which has dramatically changed the prognosis of colorectal cancer. In 1996, prior to the introduction ...
based inKloten, SWITZERLAND
Arcomed is one of the most respected infusion technology providers in the world. The company has a long history and was officially founded in 1974. Since then, arcomed ag has focused on the domain of infusion technology, offering a full range of ...
Why not involve the patient while s/he is awake in decisions about bolus drug delivery, based upon his/her pain perception? Consideration of this factor whilst maintaining the highest safety standards has been our priority in the development of our ...
based inRueil-Malmaison Cedex, FRANCE
At Advanced Accelerator Applications (AAA), we are reimagining nuclear medicine and cancer care. Our mission is to transform patients’ lives by developing and delivering targeted radioligand therapies and precision imaging radioligands for oncology. ...
LysaKare® 25g/25g solution for reduction of renal (kidney) radiation exposure during peptide-receptor radionuclide therapy with ...